Finance

Lists
532321:BOM
Zydus Lifesciences Ltd
1 124,30 INR
-1,44%
(-16,45) 1D
16 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 532321...
Open
1 137,00 INR
High
1 145,70 INR
Low
1 124,30 INR
Mkt. cap
1,12 ტრლ.
Avg. vol.
71,69 ათ.
Volume
0,00
52-wk high
1 232,00 INR
52-wk low
835,85 INR
No. of employees
30 ათ.
Open
1 137,00 INR
High
1 145,70 INR
Low
1 124,30 INR
Mkt. cap
1,12 ტრლ.
Avg. vol.
71,69 ათ.
Volume
0,00
52-wk high
1 232,00 INR
52-wk low
835,85 INR
No. of employees
30 ათ.
News stories
From web sources and news partners
Profile
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Primarily engaged in the manufacturing of generic drugs, the company ranked 100th in the Fortune India 500 list in 2020. Wikipedia
About Zydus Lifesciences Ltd
CEO-
Employees30 ათ.
Founded1952
Headquarters-
SectorPharmaceutical industry
Websitezyduslife.com
Last report
11 აგვ. 2026
Fiscal period
Q1 2027
9,48 INR / 11,15 INR
-14,98%miss
Revenue / Est. (INR)
80,17 მლრდ. / 76,87 მლრდ.
+4,30%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
61,23 მლრდ.
68,64 მლრდ.
75,87 მლრდ.
80,17 მლრდ.
Cost of goods sold
16,90 მლრდ.
18,36 მლრდ.
22,07 მლრდ.
22,40 მლრდ.
Cost of revenue
16,90 მლრდ.
18,36 მლრდ.
22,07 მლრდ.
22,40 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,34 მლრდ.
11,40 მლრდ.
32,92 მლრდ.
13,68 მლრდ.
Operating expense
31,33 მლრდ.
37,36 მლრდ.
39,40 მლრდ.
44,59 მლრდ.
Total operating expenses
48,23 მლრდ.
55,72 მლრდ.
61,48 მლრდ.
66,99 მლრდ.
Operating income
13,00 მლრდ.
12,92 მლრდ.
14,39 მლრდ.
13,18 მლრდ.
Other non operating income
1,09 მლრდ.
1,11 მლრდ.
-3,70 მლრდ.
1,06 მლრდ.
EBT including unusual items
16,93 მლრდ.
14,11 მლრდ.
16,59 მლრდ.
13,44 მლრდ.
EBT excluding unusual items
17,27 მლრდ.
14,96 მლრდ.
20,88 მლრდ.
13,63 მლრდ.
Income tax expense
4,54 მლრდ.
3,88 მლრდ.
3,18 მლრდ.
3,54 მლრდ.
Effective tax rate
26,82%
27,52%
19,19%
26,35%
Other operating expenses
17,97 მლრდ.
22,36 მლრდ.
1,28 მლრდ.
25,36 მლრდ.
Net income
12,59 მლრდ.
10,42 მლრდ.
12,72 მლრდ.
9,40 მლრდ.
Net profit margin
20,55%
15,18%
16,77%
11,72%
Earnings per share
12,76
10,96
15,84
9,48
Interest and investment income
-
-
4,24 მლრდ.
-
Interest expense
-1,01 მლრდ.
-1,30 მლრდ.
-491,00 მლნ.
-1,56 მლრდ.
Net interest expenses
-1,01 მლრდ.
-1,30 მლრდ.
3,75 მლრდ.
-1,56 მლრდ.
Depreciation and amortization charges
3,02 მლრდ.
3,60 მლრდ.
5,08 მლრდ.
5,55 მლრდ.
EBITDA
15,70 მლრდ.
15,10 მლრდ.
17,74 მლრდ.
16,53 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები